Beam Therapeutics Inc. (BEAM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q2 '19: 6K Q3 '19: 6K Q4 '19: 6K Q1 '20: 6K Q2 '20: 6K Q3 '20: 6K Q4 '20: 6K Q1 '21: 6K Q2 '21: 6K Q3 '21: 763K Q4 '21: 51.1M Q1 '22: 8.4M Q2 '22: 16.7M Q3 '22: 15.8M Q4 '22: 20M Q1 '23: 24.2M Q2 '23: 20.1M Q3 '23: 17.2M Q4 '23: 316.2M Q1 '24: 7.4M Q2 '24: 11.8M Q3 '24: 14.3M Q4 '24: 30.1M Q1 '25: 7.5M Q2 '25: 8.5M Q3 '25: 9.7M Q4 '25: 114.1M Q1 '26: 31.7M Q2 '26: 490K Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q1 '19: -13.1M Q2 '19: -17.7M Q3 '19: -18M Q4 '19: -26.4M Q1 '20: -28.4M Q2 '20: -26.3M Q3 '20: -37.3M Q4 '20: -40.8M Q1 '21: -200.4M Q2 '21: -59M Q3 '21: -69.6M Q4 '21: -63.5M Q1 '22: -76.2M Q2 '22: -82M Q3 '22: -91.3M Q4 '22: -89M Q1 '23: -98.9M Q2 '23: -102.1M Q3 '23: -108.3M Q4 '23: 132.9M Q1 '24: -104.1M Q2 '24: -104.9M Q3 '24: -106.5M Q4 '24: -100M Q1 '25: -119.3M Q2 '25: -120.2M Q3 '25: -126.8M Q4 '25: -17.4M Q1 '26: -107.2M Q2 '26: -126.6M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-270M -180M -90M 0 90M 180M 270M Q1 '19: -13.6M Q2 '19: -17.9M Q3 '19: -19M Q4 '19: -27.9M Q1 '20: -30.5M Q2 '20: -34.2M Q3 '20: -34.5M Q4 '20: -95.5M Q1 '21: -201.6M Q2 '21: -76.3M Q3 '21: -28.1M Q4 '21: -64.7M Q1 '22: -69.2M Q2 '22: -72M Q3 '22: -109.6M Q4 '22: -38.3M Q1 '23: -96.5M Q2 '23: -82.8M Q3 '23: -96.1M Q4 '23: 142.8M Q1 '24: -98.7M Q2 '24: -91.1M Q3 '24: -96.7M Q4 '24: -90.4M Q1 '25: -108.3M Q2 '25: -102.1M Q3 '25: -112.7M Q4 '25: 243.2M Q1 '26: -94.3M Q2 '26: -122.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-160M -80M 0 80M 160M 240M Q1 '19: -25.9M Q2 '19: -11.4M Q3 '19: -17M Q4 '19: -17.8M Q1 '20: -27.4M Q2 '20: -22.8M Q3 '20: -21.2M Q4 '20: -24.3M Q1 '21: -38.6M Q2 '21: -32.5M Q3 '21: 3M Q4 '21: 1.8M Q1 '22: 218.5M Q2 '22: -52.3M Q3 '22: -74.5M Q4 '22: -69.2M Q1 '23: -109.8M Q2 '23: -84.7M Q3 '23: -89.8M Q4 '23: 135.1M Q1 '24: -99.7M Q2 '24: -83M Q3 '24: -88.1M Q4 '24: -76.4M Q1 '25: -103.9M Q2 '25: -76.5M Q3 '25: -81.5M Q4 '25: -83.3M Q1 '26: -128.5M Q2 '26: -66.1M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-160M -80M 0 80M 160M 240M Q1 '19: -28.2M Q2 '19: -17.9M Q3 '19: -18.4M Q4 '19: -20M Q1 '20: -30.4M Q2 '20: -25.2M Q3 '20: -24M Q4 '20: -32.4M Q1 '21: -50.1M Q2 '21: -48.7M Q3 '21: -2.8M Q4 '21: -11.5M Q1 '22: 211.2M Q2 '22: -73.9M Q3 '22: -86.3M Q4 '22: -77.5M Q1 '23: -115.8M Q2 '23: -100.8M Q3 '23: -97.7M Q4 '23: 131.5M Q1 '24: -102.2M Q2 '24: -85M Q3 '24: -89.7M Q4 '24: -79.3M Q1 '25: -106.9M Q2 '25: -79.6M Q3 '25: -86.5M Q4 '25: -87M Q1 '26: -130.7M Q2 '26: -68.5M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '20: 49.4M Q3 '20: 50.1M Q1 '21: 60.2M Q2 '21: 62.2M Q3 '21: 66.4M Q1 '22: 68.7M Q2 '22: 70.2M Q3 '22: 70.3M Q1 '23: 72.3M Q2 '23: 76.3M Q3 '23: 79M Q1 '24: 81.7M Q2 '24: 82.3M Q3 '24: 82.4M Q1 '25: 88M Q2 '25: 102M Q3 '25: 102.6M Q1 '26: 103.3M Q2 '26: 104.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '19: -14.02 Q1 '20: -12.19 Q2 '20: -9.50 Q3 '20: -6.88 Q4 '20: -4.29 Q1 '21: -6.61 Q2 '21: -7.15 Q3 '21: -6.88 Q4 '21: -5.91 Q1 '22: -3.57 Q2 '22: -3.36 Q3 '22: -4.50 Q4 '22: -4.13 Q1 '23: -4.45 Q2 '23: -4.51 Q3 '23: -4.17 Q4 '23: -1.72 Q1 '24: -1.60 Q2 '24: -1.63 Q3 '24: -1.58 Q4 '24: -4.58 Q1 '25: -4.60 Q2 '25: -4.49 Q3 '25: -4.42 Q4 '25: -0.81 Q1 '26: -0.49 Q2 '26: -0.67 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.